Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetilistat dose-ranging study in obese adults with type 2 diabetes on metformin
ISRCTN62647464Phase 2Completed
- Sponsor
- Alizyme
- Start
- Dec 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cetilistat in obesity and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Alizyme. Primary endpoint: Absolute weight loss compared to baseline. Started Dec 2004; status: completed.
02
Drugs
cetilistat
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN62647464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62647464.